Advances in technology have given businesses access to increasingly large volumes of data, so much that it can be challenging to know how to analyse it. Yet, somewhere in this vast sea of data, there are insights waiting to be unearthed. These insights can be used to drive smarter business moves, make operations more efficient and in the case of the healthcare industry, to save lives.
McKinsey Global Institute estimates that using Big Data to inform decision making could generate up to $100 billion in value annually across the US healthcare system alone. In the pharma industry, the analysis of Big Data puts companies in a stronger position to identify new drug candidates and to develop them into life-saving medicines at a faster pace.
A key focus of Research and Development efforts at Innopharma has been in the Process Analytical Technology (PAT) space. PAT has been defined by the US Food and Drug Administration (FDA) as a mechanism to “design, analyse, and control pharmaceutical manufacturing processes through the measurement of Critical Process Parameters (CPP) which affect Critical Quality Attributes (CQA)”
The practical implementation of PAT involves the on-line or in-line integration of “smart technology” such as process control sensors to conventional process equipment and using the real-time data from the sensors to model and control the process. Of course, the application of PAT leads to the generation of large and complex datasets also known as ‘Big Data’. By harnessing the storage, distribution and processing capacity of ‘The Cloud’ innovation opportunities for Innopharma Technology has progressed. Now it is possible to apply advanced analytic against PAT generated Big Data to help decode complex manufacturing process.
It is very clear that Big Data is a genuinely game-changing technology and there are few areas of the pharmaceutical and medical industries which will be unaffected by the implementation of data analytics in the coming years. However, it’s not an area of the industry without challenges. Harvard Business Review stated in 2016 that the biggest challenge ‘by far’ when it comes to pharma and Big Data has been finding the right talent. This offers a unique opportunity to upskill in an emerging area that is crying out for qualified candidates.
We have created our MSc in Pharmaceutical Data Analytics. This new, part-time Master’s programme has been specifically developed for those who wish to become leading practitioners in the field of data analytics. And it takes just 12 months to complete.
If you’re someone who’s analytical and enjoys spotting patterns, then it’s worth considering upskilling for this emerging industry.
The course is primarily aimed at people with a minimum qualification of level 8 or higher in the fields of Science, Quality, Engineering, Computational or related disciplines.
It’s is taught in two stages. Stage one is a two-semester taught programme in Pharmaceutical Data Analytics which leads to a Postgraduate Diploma in Science in Pharmaceutical Data Analytics. Stage two is a one-semester dissertation stage leading to an MSC in Pharmaceutical Data Analytics.
There are many opportunities upon graduation of the course. Some of the roles you’ll be gaining the skills for include: data analyst, data scientist, data analytics consultant and much more.
At Innopharma, we have strong ties to the industry and we use these to help our students to achieve their career goals. If you want to be a part of the exciting new world of Big Data, this course is the perfect first step.
Interested in Finding Out More About this Course?
Visit our course page for more information or call us on (01) 4853346